Last reviewed · How we verify
CD19 and CD22 targeted prime CAR- T cells
CD19 and CD22 targeted prime CAR- T cells is a Biologic drug developed by Chongqing Precision Biotech Co., Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | CD19 and CD22 targeted prime CAR- T cells |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL (PHASE1, PHASE2)
- a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19 and CD22 targeted prime CAR- T cells CI brief — competitive landscape report
- CD19 and CD22 targeted prime CAR- T cells updates RSS · CI watch RSS
- Chongqing Precision Biotech Co., Ltd portfolio CI
Frequently asked questions about CD19 and CD22 targeted prime CAR- T cells
What is CD19 and CD22 targeted prime CAR- T cells?
CD19 and CD22 targeted prime CAR- T cells is a Biologic drug developed by Chongqing Precision Biotech Co., Ltd.
Who makes CD19 and CD22 targeted prime CAR- T cells?
CD19 and CD22 targeted prime CAR- T cells is developed by Chongqing Precision Biotech Co., Ltd (see full Chongqing Precision Biotech Co., Ltd pipeline at /company/chongqing-precision-biotech-co-ltd).
What development phase is CD19 and CD22 targeted prime CAR- T cells in?
CD19 and CD22 targeted prime CAR- T cells is in Phase 1.